

Date: 10th June, 2026

To,
BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai – 400 001

To,
National Stock Exchange of India Limited
Listing Department,
'Exchange Plaza'. C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Scrip Code No.: 533259

Symbol: HEALTHX

Dear Sir/Madam,

Sub: Intimation of the Outcome of the Meeting of the Board of Directors of Health X Platform Limited (“Company”) held on June 10, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended from time to time (“SEBI LODR Regulations”)

Pursuant to the provisions of Regulation 30 read with Schedule III and other applicable provisions of SEBI LODR Regulations, as amended from time to time, we wish to inform you that the Board of Directors (“**Board**”) of the Company, at its meeting held today on **June 10, 2026**, have considered and approved:

- (a) Based on the recommendations of the Committee of Independent Directors and the Audit Committee, the Composite Scheme of Arrangement and Amalgamation amongst Health X Platform Limited (“**Health X**” or “**Demerged Company**” or “**Transferee Company**” or “**Company**”), Microsec Resources Private Limited (“**MRPL**” or “**Resulting Company**” or “**Amalgamated Company**”), Innogrow Technologies Limited (“**ITL**” or “**Amalgamating Company**”) and Sastasundar Healthbuddy Limited (“**SHBL**” or “**Transferor Company**”) (collectively referred to as “**Companies**”) and their respective shareholders and creditors pursuant to Section 230 to 232 read with other applicable provisions of the Companies Act, 2013 and the rules framed thereunder (“**Scheme**”).
- (b) Pursuant to the effectiveness of the Scheme, equity shares will be issued as per the following Share Entitlement Ratio and Share Exchange Ratio as determined:



HEALTH X PLATFORM LIMITED

(Formerly known as Sastasundar Ventures Limited)

Regd. Office: Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata- 700 017, India
E: info@sastasundar.com | www.healthxplatform.com | P: +91 33 2282 9330 | CIN: L65993WB1989PLC047002

i. For Part II of the Scheme:

“1 (One) equity share of the Resulting Company having a face value of INR 10/- each fully paid-up shall be issued for every 3 (Three) equity shares held in the Demerged Company having a face value INR 10/- each fully paid-up”

ii. For Part IV of the Scheme:

“85,12,168 (Eighty Five Lakhs Twelve Thousand One Hundred And Sixty Eight) equity shares of the Transferee Company having a face value of INR 10/- each fully paid-up shall be issued for 45,75,830 (Forty Five Lakhs, Seventy Five Thousand Eight Hundred And Thirty) equity shares held in the Transferor Company having a face value INR 10/- each fully paid-up other than those held by Transferee Company”

(c) The appointed date for the Scheme shall mean 01 April 2026 or such other date as may be decided by the Board of Directors of the Companies and approved by the Appropriate Authority. (“**Appointed Date**”)

(d) Further, the effective date for the Scheme shall mean the last of the dates on which the certified copies of the sanction order of the Hon’ble National Company Law Tribunal, Kolkata Bench are filed with the Registrar of Companies by the Companies, and all actions set out in Clause 36 of this Scheme have been duly completed. (“**Effective Date**”)

The Scheme is, inter alia, subject to receipt of approvals from BSE Limited and the National Stock Exchange of India (collectively referred to as the “**Stock Exchanges**”), Securities Exchange Board of India (“**SEBI**”), jurisdictional National Company Law Tribunal (“**NCLT**”), Reserve Bank of India (“**RBI**”), and the shareholders and creditors (as applicable) of the companies involved in the Scheme.

The Scheme will be filed with the Stock Exchange as per the applicable provisions of Regulation 37 of the SEBI LODR Regulations read with the SEBI Master Circular bearing reference number HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, as amended from time to time.

In terms of the SEBI LODR Regulations read with SEBI Master Circular bearing reference number HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026, as amended from time to time, we are furnishing herewith the details of the Scheme as **Annexure A**.

The Board Meeting commenced at 3:20 PM. and concluded at 4:00 PM.

The above is for your information we request you to take the same on record

Thanking you,
Yours faithfully,

For and on behalf of Health X Platform Limited,

Pratap Singh
Company Secretary & Compliance Officer
Membership No: A24081

Date: 10th June 2026
Place: Kolkata

Annexure A

Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular bearing reference number HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated 30 January 2026 are provided hereunder:

S. No.	Particulars	Details
1.	Name of the entities forming part of the arrangement, details in brief such as, size, turnover etc. & brief details of the division to be demerged under the composite scheme of arrangement	<p>The Composite scheme of arrangement is amongst Heath X Platform Limited (<i>formerly known as Sastasundar Ventures Limited</i>) having (Demerged/Transferee Company), Microsec Resources Private Limited having (Resulting/Amalgamated Company), Innogrow Technologies Limited (Amalgamating Company), Sastasundar Healthbuddy Limited (Transferor Company) and their respective shareholders and creditors under section 230-232 and other applicable provisions of the Companies Act, 2013 (“Scheme”).</p> <p>Brief details of the companies involved in the Scheme as follows:</p> <p>(i) Health X Platform Limited (<i>formerly known as Sastasundar Ventures Limited</i>) (Demerged/Transferee Company). As per the standalone audited financials for the year ended 31st March 2026, the Demerged/Transferee Company has total book value of assets of INR 27,102.11 lakhs and a turnover of INR 75.98 lakhs and as per consolidated audited financials for the year ended 31st March 2026, the Demerged/Transferee Company has total book value of assets of INR 93,576.87 lakhs and a turnover of INR 1,37,753.67 lakhs including other income of INR 5,827.08 lakhs.</p> <p>(ii) Microsec Resources Private Limited (Resulting/Amalgamated Company). As per the audited financials for the year ended 31st March 2026, the Resulting/Amalgamated Company has total assets of INR 3,848.31 lakhs and turnover of INR 181.48 lakhs including other income of INR 0.47 lakhs.</p> <p>(iii) Innogrow Technologies Limited (Amalgamating</p>

S. No.	Particulars	Details								
		<p>Company). As per the audited financials for the year ended 31st March 2026, the Amalgamating Company has total assets of INR 8,953.81 lakhs and turnover consisting of other income of INR 1,331.79 lakhs.</p> <p>(iv) Sastasundar Healthbuddy Limited (Transferor Company). As per the audited financials for the year ended 31st March 2026, the Transferor Company has total assets of INR 76,033.74 lakhs and turnover of INR 1,35,969.66 lakhs including other income of 5,620.11 lakhs.</p> <p>The Scheme primarily has three parts. Brief details of the Scheme are provided below:</p> <ul style="list-style-type: none"> (i) Demerger of the Demerged Undertaking (<i>as defined in the Scheme</i>) from Demerged Company into the Resulting Company; (ii) Amalgamation of Amalgamating Company with and into the Amalgamated Company; and (iii) Amalgamation of the Transferor Company with and into the Transferee Company. <p>Brief Details of the Demerged Undertaking:</p> <p>The division of the Demerged Company which is mainly engaged in financing of loans, investment in shares and securities, investment in real estate, financial consultancy, professional fees, wealth management, financial planning, distribution and related services, directly and through its subsidiaries.</p>								
2.	Turnover of the demerged division and as percentage to the total turnover of the listed entity in the immediately preceding financial year / based on financials of the last financial year;	<table border="1"> <thead> <tr> <th>Particulars</th> <th>Turnover (in lakhs)*</th> </tr> </thead> <tbody> <tr> <td>Demerged division</td> <td>1,519.05</td> </tr> <tr> <td>Total</td> <td>1,37,753.67</td> </tr> <tr> <td>Percentage</td> <td>1.10%</td> </tr> </tbody> </table> <p><i>*for the year ending 31st March 2026 as per the consolidated financial statements of Health X.</i></p>	Particulars	Turnover (in lakhs)*	Demerged division	1,519.05	Total	1,37,753.67	Percentage	1.10%
Particulars	Turnover (in lakhs)*									
Demerged division	1,519.05									
Total	1,37,753.67									
Percentage	1.10%									

S. No.	Particulars	Details
3.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arms’ length”	<p>Yes. In accordance with General Circular No. 30/2014 dated 17th July 2014, issued by the Ministry of Corporate Affairs, transactions resulting from compromises, arrangements, and amalgamations under the Companies Act 2013, are not subject to the requirements of Section 188 of Companies Act, 2013.</p> <p>The transactions contemplated in the Scheme are being undertaken at arms’ length in accordance with the Share Exchange Ratio and Share Entitlement Ratio which has been arrived at based on the valuation report dated 10th June 2026 issued by Mr. Sagar Mehta (Partner, SSPA & Co, Chartered Accountants) (Registration No. IBBI/RV-E/06/2020/126), recommending the Share Exchange Ratio and Share Entitlement Ratio.</p> <p>Jajodia Equity Advisors Services Limited, an independent SEBI registered Category- I Merchant Banker registered with SEBI having Registration Number - INM000013448, has issued a fairness opinion stating that the Share Exchange Ratio and Share Entitlement Ratio is fair from a financial point of view.</p>
4.	Area of business of the entities	<p>(i) Demerged/Transferee Company is focusing largely on the following business segments:</p> <p>(a) Financial Services - Engaged in financing of loans, investment in shares and securities, investment in real estate, financial consultancy, professional fees, wealth management, financial planning, distribution and related services.</p> <p>(b) Healthcare Services - Engaged in the business of trading and distribution of medicines and pharmaceutical products to retailers and operating an E-commerce platform for sale of medicines, pharmaceuticals, and diagnostics.</p> <p>(ii) Resulting/Amalgamated Company is a registered Non-Deposit Accepting Non-Banking Financial Institution (“NBFI”), a non-banking financial company</p>

S. No.	Particulars	Details
		<p>having Certificate of Registration under RBI Act, 1934. (Certificate of Registration No. being B-05.06241) and is involved in business of financing.</p> <p>(iii) Amalgamating Company was incorporated to principally engage in the business of providing end-to-end IT, digital technology services and IT-enabled services.</p> <p>(iv) Transferor Company is principally engaged in the business of trading and distribution of medicine and other pharmaceutical products to various retailers. It also operates an E-commerce platform for sale of medicines, other pharmaceuticals products and diagnostics, through its subsidiary.</p>
5.	<p>Rationale for the demerger of the Demerged Undertaking from the Demerged Company into the Resulting Company</p>	<p>The Scheme is intended to restructure the aforesaid Companies and consolidate their business in a manner which is expected to enable better realization of potential of their business, yield beneficial results and enhanced value creation for the said Companies, their respective shareholders and stakeholders. The Composite Scheme of Arrangement and Amalgamation between the Companies will inter alia have the following benefits:</p> <p>Demerger of the Demerged Undertaking (as defined in the Scheme) from the Demerged Company into the Resulting Company</p> <p>The Demerged Company is a multi-business corporate engaged in the business of providing healthcare and financial services which is carried on by the Demerged Company directly and through its subsidiaries. This Scheme is in the best interests of the Companies and their respective shareholders, employees, creditors and other stakeholders on account of following benefits:</p> <p>(a) Demerger shall lead to creation of a separate, distinct and focused entity housing the Financial Services Business (as defined hereinafter), leading to greater</p>

S. No.	Particulars	Details
		<p>operational efficiencies and enabling value unlocking of Financial Services Business (<i>as defined hereinafter</i>) within the Resulting Company and of the other division in the Demerged Company and giving option of investment to public shareholders into respective businesses and enable their independent value discovery;</p> <p>(b) Segregating the businesses would enable independent business opportunities, attracting different sets of strategic partners and other stakeholders and would bring about greater internal control over business processes / ease in decision making;</p> <p>(c) Independent group structure for each of the business segments of the group will ensure required depth and focus on each of the segments and adoption of strategies necessary for the growth of the respective segments. The structure shall provide independence to the management in decisions regarding the use of their respective cash flows for dividends or capital expenditure in their respective businesses;</p> <p>(d) Cost savings are expected to flow from more focused operational efforts, rationalization, standardization and simplification of business processes, productivity improvements, and the elimination of duplication, and optimum rationalization of administrative expenses and utilization of human resources.</p>
	<p>Rationale for the Merger/Amalgamation of: (i) the Amalgamating Company with and into the Amalgamated Company; and (ii) the Transferor Company with and into the Transferee Company</p>	<p>1. Amalgamation of the Amalgamating Company with and into the Amalgamated Company:</p> <p>The Scheme is intended to restructure these Companies and consolidate their businesses in a manner which is expected to enable better realization of potential of their businesses, yield beneficial results and enhanced value creation for the said Companies, their respective shareholders and stakeholders. This Scheme is in the best interest of the said Companies and their respective shareholders, employees, creditors and other</p>

S. No.	Particulars	Details
		<p>stakeholders on account of following benefits:</p> <ul style="list-style-type: none"> (a) The business of the Amalgamating Company and the Amalgamated Company can be combined / adjusted and carried forward conveniently with combined strength and would result in consolidation of the Companies, streamlining the corporate structure and pooling of their resources into a single entity. (b) Consolidation of the businesses of the Amalgamating Company and the Amalgamated Company, to achieve optimal and efficient utilization of capital, resulting in lesser overheads including administrative, managerial, and other expenditure, optimal utilization of resources, and provide a common governance structure. (c) Unification and streamlining of legal and regulatory compliances currently required to be carried out by both the Amalgamating Company and the Amalgamated Company. <p>2. Amalgamation of the Transferor Company with and into the Transferee Company</p> <p>SHBL is engaged in the business of trading and distribution of medicine and other pharmaceutical products to various retailers. SHBL, through its subsidiary, also operates an e-commerce platform for sale of medicines, other pharmaceuticals products and diagnostics. The aforesaid healthcare business of SHBL has been nurtured over a period of time. This Scheme is in the best interest of the Companies and their respective shareholders, employees, creditors and other stakeholders on account of following benefits:</p> <ul style="list-style-type: none"> (a) As the primary operational entity in the Healthcare Services segment, the amalgamation of the Transferor Company with the Transferee Company will consolidate resources into a single entity and maximize overall

S. No.	Particulars	Details
		<p>shareholder value.</p> <p>(b) Consolidation of the businesses of the Transferor Company and the Transferee Company, for creation of a larger unified entity and to achieve optimal and efficient utilization of capital, resulting in lesser overheads including administrative, managerial, and other expenditure, optimal utilization of resources, and provide a common governance structure.</p> <p>(c) Pooling of knowledge and expertise of both the Companies and align with the business plans to meet long-term objectives and enhance operational and management efficiencies.</p> <p>(d) Unification and streamlining of legal and regulatory compliances currently required to be carried out by both the Transferor Company and the Transferee Company.</p> <p>(e) The amalgamation of the Transferor Company with the Transferee Company will result in the creation of a unified healthcare entity, enabling streamlined management, focused investment decisions, and optimal utilization of cash flows for dividends or capital expenditure in the consolidated healthcare business.</p>
6.	<p>In case of cash consideration – amount or otherwise share exchange ratio – required from registered valuer</p>	<p>There is no cash consideration involved in the Scheme.</p> <p>Upon the coming into effect of this Scheme and in consideration of the transfer and vesting of the Demerged Undertaking of Demerged Company, the Resulting Company shall without any further act or deed, shall, issue and allot equity shares to the shareholders of Demerged Company whose name appear in the register of members of Demerged Company on the Record Date 1 or to such of their heirs, executors, administrators or the successor-in-title, shares in the following mode:</p>

S. No.	Particulars	Details
		<p>1. <u>To the shareholders of Demerged Company</u></p> <p><i>“1 (One) equity share of the Resulting Company having a face value of INR 10/- each fully paid-up shall be issued for every 3 (Three) equity shares held in the Demerged Company having a face value INR 10/- each fully paid-up.”</i></p> <p>2. <u>To the shareholders of Transferor Company</u></p> <p><i>“85,12,168 (Eighty-five lakhs, twelve thousand, one hundred and sixty- eight) equity shares of the Transferee Company having a face value of INR 10/- each fully paid-up shall be issued for 45,75,830 (Forty-five lakhs, seventy-five thousand, eight hundred and thirty) equity shares held in the Transferor Company having a face value INR 10/- each fully paid-up other than those held by Transferee Company”</i></p> <p>The Share Exchange Ratio and Share Entitlement Ratio has been arrived at based on the valuation report dated 10th June 2026 issued by Mr. Sagar Mehta (Partner, SSPA & Co, Chartered Accountants) (Registration No. IBBI/RV-E/06/2020/126), recommending the Share Exchange Ratio and Share Entitlement Ratio.</p> <p>Jajodia Equity Advisors Services Limited, an independent SEBI registered Category I Merchant Banker (SEBI Regn. No.: INM000013448), has issued a fairness opinion stating that the Share Exchange Ratio and Share Entitlement Ratio is fair from a financial point of view.</p> <p>No shares would be issued for the amalgamation of the Amalgamating Company with and into the Amalgamated Company, as immediately upon the effectiveness of the Demerger, the Amalgamating Company shall become the wholly owned subsidiary of the Amalgamated Company and the entire paid-up share capital of the Amalgamating Company will be held by the Amalgamated Company. Accordingly, upon</p>

S. No.	Particulars	Details																								
		amalgamation of the Amalgamating Company with and into Amalgamated Company, there will be no issue of shares as consideration for the said amalgamation and the entire share capital of the Amalgamating Company shall stand extinguished and cancelled.																								
7.	Brief details of change in shareholding pattern (if any) of the listed entity	<p>Upon the Scheme becoming effective, the Transferee Company will issue equity shares as mentioned in point 6 above to the shareholders of the Transferor Company as on the Record Date (as defined in the Scheme) and all the shares of the Transferor Company shall stand extinguished.</p> <p>Accordingly, upon the Scheme becoming effective, the following change will occur in the shareholding pattern of the Transferee Company (listed entity) i.e. Health X Platform Limited:</p> <table border="1"> <thead> <tr> <th rowspan="2">Status</th> <th colspan="2">Pre-Scheme</th> <th colspan="2">Post-Scheme</th> </tr> <tr> <th>No. of shares</th> <th>% of holding</th> <th>No. of shares</th> <th>% of holding</th> </tr> </thead> <tbody> <tr> <td>Promoter & Promoter Group</td> <td>2,35,60,627</td> <td>74.07%</td> <td>2,35,60,627</td> <td>58.43%</td> </tr> <tr> <td>Public</td> <td>82,49,873</td> <td>25.93%</td> <td>1,67,62,041</td> <td>41.57%</td> </tr> <tr> <td>Total</td> <td>3,18,10,500</td> <td>100%</td> <td>4,03,22,668</td> <td>100%</td> </tr> </tbody> </table>	Status	Pre-Scheme		Post-Scheme		No. of shares	% of holding	No. of shares	% of holding	Promoter & Promoter Group	2,35,60,627	74.07%	2,35,60,627	58.43%	Public	82,49,873	25.93%	1,67,62,041	41.57%	Total	3,18,10,500	100%	4,03,22,668	100%
Status	Pre-Scheme			Post-Scheme																						
	No. of shares	% of holding	No. of shares	% of holding																						
Promoter & Promoter Group	2,35,60,627	74.07%	2,35,60,627	58.43%																						
Public	82,49,873	25.93%	1,67,62,041	41.57%																						
Total	3,18,10,500	100%	4,03,22,668	100%																						
	Brief details of change the change in the shareholding pattern (if any) of all entities	<p>Upon the Scheme becoming effective, the following change will occur in the shareholding pattern of Microsec Resources Private Limited (Resulting/Amalgamated Company):</p> <table border="1"> <thead> <tr> <th rowspan="2">Status</th> <th colspan="2">Pre-Scheme</th> <th colspan="2">Post-Scheme</th> </tr> <tr> <th>No. of shares</th> <th>% of holding</th> <th>No. of shares</th> <th>% of holding</th> </tr> </thead> <tbody> <tr> <td>Promoter & Promoter Group</td> <td>25,81,357</td> <td>100%</td> <td>78,53,542</td> <td>74.07%</td> </tr> <tr> <td>Public</td> <td>-</td> <td>-</td> <td>27,49,958</td> <td>25.93%</td> </tr> <tr> <td>Total</td> <td>25,81,357</td> <td>100%</td> <td>1,06,03,500</td> <td>100%</td> </tr> </tbody> </table>	Status	Pre-Scheme		Post-Scheme		No. of shares	% of holding	No. of shares	% of holding	Promoter & Promoter Group	25,81,357	100%	78,53,542	74.07%	Public	-	-	27,49,958	25.93%	Total	25,81,357	100%	1,06,03,500	100%
Status	Pre-Scheme			Post-Scheme																						
	No. of shares	% of holding	No. of shares	% of holding																						
Promoter & Promoter Group	25,81,357	100%	78,53,542	74.07%																						
Public	-	-	27,49,958	25.93%																						
Total	25,81,357	100%	1,06,03,500	100%																						

S. No.	Particulars	Details																																								
		<p>Upon the Scheme becoming effective, the following change will occur in the shareholding pattern of Innogrow Technologies Limited (Amalgamating Company):</p> <table border="1"> <thead> <tr> <th rowspan="2">Status</th> <th colspan="2">Pre-Scheme</th> <th colspan="2">Post-Scheme</th> </tr> <tr> <th>No. of shares</th> <th>% of holding</th> <th>No. of shares</th> <th>% of holding</th> </tr> </thead> <tbody> <tr> <td>Promoter & Promoter Group</td> <td>3,31,018</td> <td>100%</td> <td colspan="2" rowspan="3">Not Applicable – ITL shall be dissolved pursuant to Scheme.</td> </tr> <tr> <td>Public</td> <td>-</td> <td>-</td> </tr> <tr> <td>Total</td> <td>3,31,018</td> <td>100%</td> </tr> </tbody> </table> <p>Upon the Scheme becoming effective, the following change will occur in the shareholding pattern of Sastasundar Healthbuddy Limited (Transferor Company):</p> <table border="1"> <thead> <tr> <th rowspan="2">Status</th> <th colspan="2">Pre-Scheme</th> <th colspan="2">Post-Scheme</th> </tr> <tr> <th>No. of shares</th> <th>% of holding</th> <th>No. of shares</th> <th>% of holding</th> </tr> </thead> <tbody> <tr> <td>Promoter & Promoter Group</td> <td>1,71,00,160</td> <td>78.89%</td> <td colspan="2" rowspan="3">Not Applicable – SHBL shall be dissolved pursuant to Scheme.</td> </tr> <tr> <td>Public</td> <td>45,75,830</td> <td>21.11%</td> </tr> <tr> <td>Total</td> <td>2,16,75,990</td> <td>100%</td> </tr> </tbody> </table>	Status	Pre-Scheme		Post-Scheme		No. of shares	% of holding	No. of shares	% of holding	Promoter & Promoter Group	3,31,018	100%	Not Applicable – ITL shall be dissolved pursuant to Scheme.		Public	-	-	Total	3,31,018	100%	Status	Pre-Scheme		Post-Scheme		No. of shares	% of holding	No. of shares	% of holding	Promoter & Promoter Group	1,71,00,160	78.89%	Not Applicable – SHBL shall be dissolved pursuant to Scheme.		Public	45,75,830	21.11%	Total	2,16,75,990	100%
Status	Pre-Scheme			Post-Scheme																																						
	No. of shares	% of holding	No. of shares	% of holding																																						
Promoter & Promoter Group	3,31,018	100%	Not Applicable – ITL shall be dissolved pursuant to Scheme.																																							
Public	-	-																																								
Total	3,31,018	100%																																								
Status	Pre-Scheme		Post-Scheme																																							
	No. of shares	% of holding	No. of shares	% of holding																																						
Promoter & Promoter Group	1,71,00,160	78.89%	Not Applicable – SHBL shall be dissolved pursuant to Scheme.																																							
Public	45,75,830	21.11%																																								
Total	2,16,75,990	100%																																								
8.	Whether listing would be sought for the resulting entity.	Yes. The shares issued by the Resulting Company to the shareholders of the Demerged Company would be listed on BSE Limited and the National Stock Exchange of India Limited, subject to necessary approvals.																																								

For and on behalf of Health X Platform Limited,

Pratap Singh
Company Secretary & Compliance Officer
Membership No: A24081



HEALTH X PLATFORM LIMITED

(Formerly known as Sastasundar Ventures Limited)

Regd. Office: Azimganj House, 2nd Floor, 7 Abanindra Nath Thakur Sarani (Formerly Camac Street), Kolkata- 700 017, India
E: info@sastasundar.com | www.healthxplatform.com | P: +91 33 2282 9330 | CIN: L65993WB1989PLC047002